| MDL | MFCD22572350 |
|---|---|
| Molecular Weight | 447.51 |
| Molecular Formula | C23H21N5O3S |
| SMILES | O=C(C1=CC(C2=CC(C)=CN=C2)=NC=C1C3=NC=CS3)NCC4=NC(OC)=C(OC)C=C4 |
MK-3697 is an isonicotinamide small molecule, acting as a potent and selective Orexin 2 receptor antagonist with Ki = 0.95 nM. IC50 value: 0.95 nM(Ki) Target: Orexin 2 receptor antagonist MK-3697 is a highly potent, orally bioavailable selective orexin 2 receptor antagonists (2-SORAs) that possess acceptable profiles for clinical development. Herein we report additional SAR studies within the “triaryl” amide 2-SORA series focused on improvements in compound stability in acidic media and time-dependent inhibition of CYP3A4. MK-3697 has improved stability and TDI profiles as well as excellent sleep efficacy across species.
Solid
Room temperature in continental US; may vary elsewhere.
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
DMSO : 22.5 mg/mL ( 50.28 mM ; Need ultrasonic and warming)
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.2346 mL | 11.1729 mL | 22.3459 mL |
| 5 mM | 0.4469 mL | 2.2346 mL | 4.4692 mL |
| 10 mM | 0.2235 mL | 1.1173 mL | 2.2346 mL |